Alluvi, known as BI 4744, presents a significant breakthrough in weight management treatment. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates impressive efficacy in clinical assessments, arguably surpassing existing